1. Macrophages are the major microenvironmental component of bone-metastatic prostate cancer in patients.
2. Macrophages drive anti-androgen resistance through cytokine activin A, which induces fibronectin (FN1)-integrin alpha 5 (ITGA5)-tyrosine kinase Src (SRC) signaling cascade in prostate cancer cells.
3. Macrophage depletion or SRC inhibition using a novel specific inhibitor significantly inhibited resistant growth.
The article is generally reliable and trustworthy, as it provides evidence from a novel in vivo model to support its claims and is based on bioinformatics analysis of patient transcriptomics datasets. The authors have also provided potential therapeutic approaches to treat this deadly disease, such as macrophage depletion or SRC inhibition using a novel specific inhibitor. However, there are some points that could be improved upon. For example, the article does not explore any counterarguments to its claims or present both sides of the argument equally. Additionally, it does not mention any possible risks associated with the proposed treatments or provide evidence for the claims made about their efficacy. Furthermore, there is no discussion of how these treatments may affect other aspects of health or quality of life for those undergoing them. Finally, there is some promotional content in the article that could be toned down to make it more objective and unbiased.